File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents

TitleAcceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents
Authors
KeywordsAttitudes
Cervical cancer
Health expenditures
Hong Kong
HPV vaccines
Issue Date2013
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2013, v. 32 n. 1, p. 78-84 How to Cite?
AbstractBackground: Organized population-based HPV vaccination programs can be effective in reducing the burden of cervical cancer, especially in the absence of a comprehensive cervical screening program (e.g. Hong Kong). Assessment of vaccine acceptability is important when evaluating the feasibility and cost-effectiveness of such vaccination programs. Methods: To provide a more representative and updated assessment on the acceptability of female adolescent HPV vaccination in Hong Kong, we conducted surveys in 2008 among 1022 mothers with daughters aged ≤18 years through random digit-dialing telephone interviewing and 2167 schoolgirls aged 11–18 years using two-stage stratified cluster sampling. We conducted the maternal survey again in 2012 with an independent group of 1005 mothers. Results: In 2008, 2.4% (95% confidence interval [CI] = 1.8–3.2%) of the recruited schoolgirls reported having received HPV vaccination. In 2012, the mothers reported that 9.1% (7.0–11.6%) of their daughters who were in the same age range (11–18 years) as the schoolgirls had been vaccinated (p < 0.01). Regarding acceptability, 27.5% (24.8–30.4%) and 37.6% (34.5–40.8%) of the mothers were willing to have their daughters vaccinated at market price in 2008 and 2012 (p < 0.01), respectively. 27.1% (25.2–29.1%) of the schoolgirls were willing to receive HPV vaccination at market price in 2008. The willingness to pay for full-course vaccination among mothers had a median of US$128/HK$1000 (50% central range = US$64–192/HK$500–1500), i.e. substantially lower than the current market price. Conclusions: The gap between acceptability and actual uptake of HPV vaccination among adolescent girls suggested that coverage is likely to be low without an organized HPV vaccination program, although the difference might be partially attributed to the possibility that at the time of the interview female adolescents who were willing to be vaccinated had not yet taken action. Policymakers should devise tailored, targeted and efficient vaccination strategies to achieve universal coverage for an effectively organized HPV vaccination program.
Persistent Identifierhttp://hdl.handle.net/10722/194832
ISSN
2019 Impact Factor: 3.143
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChoi, CWen_US
dc.contributor.authorLeung, GMen_US
dc.contributor.authorWoo, PPen_US
dc.contributor.authorJit, Men_US
dc.contributor.authorWu, JTKen_US
dc.date.accessioned2014-02-17T02:14:41Z-
dc.date.available2014-02-17T02:14:41Z-
dc.date.issued2013en_US
dc.identifier.citationVaccine, 2013, v. 32 n. 1, p. 78-84en_US
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/10722/194832-
dc.description.abstractBackground: Organized population-based HPV vaccination programs can be effective in reducing the burden of cervical cancer, especially in the absence of a comprehensive cervical screening program (e.g. Hong Kong). Assessment of vaccine acceptability is important when evaluating the feasibility and cost-effectiveness of such vaccination programs. Methods: To provide a more representative and updated assessment on the acceptability of female adolescent HPV vaccination in Hong Kong, we conducted surveys in 2008 among 1022 mothers with daughters aged ≤18 years through random digit-dialing telephone interviewing and 2167 schoolgirls aged 11–18 years using two-stage stratified cluster sampling. We conducted the maternal survey again in 2012 with an independent group of 1005 mothers. Results: In 2008, 2.4% (95% confidence interval [CI] = 1.8–3.2%) of the recruited schoolgirls reported having received HPV vaccination. In 2012, the mothers reported that 9.1% (7.0–11.6%) of their daughters who were in the same age range (11–18 years) as the schoolgirls had been vaccinated (p < 0.01). Regarding acceptability, 27.5% (24.8–30.4%) and 37.6% (34.5–40.8%) of the mothers were willing to have their daughters vaccinated at market price in 2008 and 2012 (p < 0.01), respectively. 27.1% (25.2–29.1%) of the schoolgirls were willing to receive HPV vaccination at market price in 2008. The willingness to pay for full-course vaccination among mothers had a median of US$128/HK$1000 (50% central range = US$64–192/HK$500–1500), i.e. substantially lower than the current market price. Conclusions: The gap between acceptability and actual uptake of HPV vaccination among adolescent girls suggested that coverage is likely to be low without an organized HPV vaccination program, although the difference might be partially attributed to the possibility that at the time of the interview female adolescents who were willing to be vaccinated had not yet taken action. Policymakers should devise tailored, targeted and efficient vaccination strategies to achieve universal coverage for an effectively organized HPV vaccination program.-
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine-
dc.relation.ispartofVaccineen_US
dc.subjectAttitudes-
dc.subjectCervical cancer-
dc.subjectHealth expenditures-
dc.subjectHong Kong-
dc.subjectHPV vaccines-
dc.titleAcceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescentsen_US
dc.typeArticleen_US
dc.identifier.emailChoi, CW: hcchoi@hku.hken_US
dc.identifier.emailLeung, GM: gmleung@hku.hken_US
dc.identifier.emailWu, JTK: joewu@hku.hken_US
dc.identifier.authorityLeung, GM=rp00460en_US
dc.identifier.authorityWu, JTK=rp00517en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2013.10.068-
dc.identifier.pmid24188759-
dc.identifier.scopuseid_2-s2.0-84891955150-
dc.identifier.hkuros227776en_US
dc.identifier.volume32en_US
dc.identifier.issue1en_US
dc.identifier.spage78en_US
dc.identifier.epage84en_US
dc.identifier.isiWOS:000329684700014-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats